# Revolution Medicines

Source: https://onco.cc/companies/revolution-medicines/  
OnCo record `revolution-medicines` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Revolution Medicines is the leading RAS company; its pan-RAS pill daraxonrasib (Rasonque) was approved in the US in August 2026 for previously treated metastatic pancreatic cancer.

## Summary

Revolution Medicines, based in Redwood City, California, and listed as RVMD, is the leading RAS company. On 26 August 2026 the FDA approved daraxonrasib, sold as Rasonque, for adults with metastatic pancreatic adenocarcinoma who have had at least one prior systemic therapy or are not candidates for multiagent systemic therapy. Its pipeline pairs daraxonrasib, a pan-RAS inhibitor, with elironrasib, selective for G12C in the active state, and zoldonrasib against G12D, tested in the RASolute and RASolve phase 3 programmes, and the company expanded its credit facility in 2025 to fund a launch. OnCo links it to pancreatic ductal adenocarcinoma, to the KRAS roadmap from undruggable through G12C to pan-RAS, to the bottleneck of undruggable drivers, and to the idea of covalent chemistry for RAS mutations that still have no drug. Whether daraxonrasib is tolerable enough for long-term use is the open question. Daraxonrasib has its own page.

## Fields

- Kind: Company
- Last checked: 2026-10-29
- Also known as: EQRx International, Inc.; EQRx
- HQ: Redwood City, CA
- Type: biotech
- Website: https://www.revmed.com
- Ticker: RVMD

## Notes

- Checked 29 October 2026: the company's Form 8-K of 26 August 2026 states that on that day the FDA approved RASONQUE (daraxonrasib) for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy. Its 8-K of 13 October 2026 reports that the approval triggered a 250 million dollar Royalty Pharma loan tranche, drawn on 8 October 2026. Press reports of acquisition talks with Merck and AbbVie in January 2026 did not lead to an announced deal; Merck's talks were reported to have ended over price. The company remained independent and listed as of these filings.

## Sources

- Official website: https://www.revmed.com
- 8-K on FDA approval of Rasonque (SEC, 26 August 2026): https://www.sec.gov/Archives/edgar/data/1628171/000119312526366931/rvmd-20260826.htm

## Connected records

- fronts: [Targeted Therapy](https://onco.cc/fronts/targeted-therapy/)
- drugs: [Daraxonrasib](https://onco.cc/drugs/daraxonrasib/), [Elironrasib](https://onco.cc/drugs/elironrasib/), [Zoldonrasib](https://onco.cc/drugs/zoldonrasib/)
- trials: [RASolute 302](https://onco.cc/trials/rasolute-302/), [Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)](https://onco.cc/trials/nct06881784/), [Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)](https://onco.cc/trials/nct07252232/), [Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma](https://onco.cc/trials/nct07491445/), [Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors](https://onco.cc/trials/nct06128551/), [Study of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Zoldonrasib as First Line Treatment in Metastatic Non-squamous RAS G12D-Mu](https://onco.cc/trials/nct07777822/), [Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors](https://onco.cc/trials/nct07397338/), [Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC](https://onco.cc/trials/nct06162221/), [Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors](https://onco.cc/trials/nct06445062/), [Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS](https://onco.cc/trials/nct05379985/), [Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors](https://onco.cc/trials/nct06040541/), [Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mut](https://onco.cc/trials/nct07805954/), [Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-muta](https://onco.cc/trials/nct07621718/)
- cancers: [Borderline resectable pancreatic ductal adenocarcinoma](https://onco.cc/cancers/borderline-resectable-pdac/), [KRAS G12C-mutant pancreatic ductal adenocarcinoma](https://onco.cc/cancers/kras-g12c-pdac/), [Locally advanced unresectable pancreatic ductal adenocarcinoma](https://onco.cc/cancers/locally-advanced-pdac/), [Metastatic pancreatic ductal adenocarcinoma](https://onco.cc/cancers/metastatic-pdac/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/), [Resectable pancreatic ductal adenocarcinoma](https://onco.cc/cancers/resectable-pdac/)
- key papers: [Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy](https://onco.cc/key-papers/paper-holderfield-ras-on-multi-selective-inhibitor-nature-2024/)
- roadmaps: [KRAS roadmap: undruggable → G12C → pan-RAS](https://onco.cc/roadmaps/kras-roadmap/), [Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveillance question](https://onco.cc/roadmaps/pancreatic-roadmap/)
- ideas: [Covalent chemistry for the RAS mutations that still have no drug](https://onco.cc/ideas/idea-bio1-pan-ras-covalent-g12d/), [RAS inhibitor combinations and sequence: pan-RAS plus G12D-selective, plus chemotherapy, and what to give after progression](https://onco.cc/ideas/idea-pdac-ras-inhibitor-combinations-and-sequencing/)
- technologies: [KRAS & RAS inhibitors](https://onco.cc/technologies/kras-inhibitors/)
- bottlenecks: [The undruggable drivers](https://onco.cc/bottlenecks/b-undruggable-targets/)
- companies: [Bain Capital Life Sciences](https://onco.cc/companies/bain-capital-life-sciences/), [Boxer Capital](https://onco.cc/companies/boxer-capital/)

---
JSON: https://onco.cc/api/v1/entities/revolution-medicines.json